A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments, Inc., Jointly Announce Release of ALGEA 2 Clinical Trial Results

Investigating Highland's Electrosonic Stimulation ("ESStim™") Technology to Treat Chronic Osteoarthritis Knee Pain

What To Know

  •   He completed his Neurology Residency at University of Sao Paulo, post-doctoral training in Neuroscience at Beth Israel Deaconess Medical Center in Boston and was a visiting fellow in Neurophysiology at Federal University of Pernambuco as well as in Clinical Neurophysiology at University of Goettingen, Germany.
  • He is a Professor of Physical Medicine and Rehabilitation at Harvard Medical School and a Professor in the Department of Epidemiology Harvard T.

Spaulding Rehabilitation Hospital at Harvard Medical School and Highland Instruments, Inc., (“Highland”) jointly today announced clinical results of a NIH1 Sponsored Phase II Clinical Trial investigating Highland Instruments’ novel noninvasive neuromodulation technology Electrosonic Stimulation2 (“ESStim™”) to treat Chronic Osteoarthritis Knee Pain3 (ALGEA 2).

The double-blinded randomized controlled trial studied 64 patients that underwent a course of Highland’s ESStim™ therapy, given 20 minutes/day over 10 days and were assessed up to 8 weeks post therapy. Study end-points were successfully achieved, with clinically and statistically significant improvements in patient pain reduction, reduced drug use, and improved biomechanics. At 1 month post ESStim™ therapy, patient Visual Analogue Scale (VAS) pain scores were reduced by ~53% (Active) vs ~22 % (SHAM) (p<0.05). Additionally, Active ESStim™ therapy patients consumed approximately 1/3 of pain medications vs. SHAM patients through the trial (assessed as Acetaminophen Equivalent use per day).

Spaulding Principal Investigator, Felipe Fregni, MD, PhD, MMSc, MPH, MEd, stated “We have seen great results with ESStim™ across the chronic pain and movement disorder indications.  While the data speaks for itself, such as the sustained reduced pain in the chronic pain patients and improved mobility in the Parkinson’s patients, a noninvasive approach which can improve patient’s quality of life without the side-effects of drugs is very exciting.”

Dr. Felipe Fregni is the Director of the Spaulding Neuromodulation Center. He has an M.D. and Ph.D. from University of Sao Paulo, M.M.Sc. Scholars in Clinical Science Program at Harvard Medical School and M.P.H. Clinical Effectiveness at Harvard School of Public Health and a Masters of Education (M.Ed.) from Harvard Graduate School of Education.  He completed his Neurology Residency at University of Sao Paulo, post-doctoral training in Neuroscience at Beth Israel Deaconess Medical Center in Boston and was a visiting fellow in Neurophysiology at Federal University of Pernambuco as well as in Clinical Neurophysiology at University of Goettingen, Germany. He is a Professor of Physical Medicine and Rehabilitation at Harvard Medical School and a Professor in the Department of Epidemiology Harvard T.H. Chan School of Public Health.

Electrosonic Stimulation (“ESStim™”), an innovative noninvasive electrosonic brain stimulation technology to treat chronic pain (from osteoarthritis, lower back pain, diabetic neuropathic pain, carpal tunnel syndrome pain). ESStim™ has also been successfully implemented in the Parkinson’s disease population and is currently being explored to treat Opioid Use Disorder. Highland previously received 510(k)[4] premarket clearance for the ESStim™ 001, which implements ESStim™ technology.

Other clinical trials in the news.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The study is designed to assess the clinical utility and workflow benefits of Swoop® system images acquired at infusion centers and clinics to help physicians detect amyloid-related imaging abnormalities (ARIA) in Alzheimer’s patients receiving amyloid-targeting therapy at the times specified in the labeling (before the fifth, seventh, and fourteenth infusions).
“Tom and I have more than 50 years of experience,” Harp adds. “The decision to found Polymer Medical was done after careful consideration of the landscape and market opportunity; we will raise the level of competition and quality for customers.” Polymer Medical is located in a newly refurbished plant is at 168 Thorn Ave., Orchard Park, N.Y.
The RWE Program will expand Summus Laser's Class IV Laser Therapy research to generate validated and statistically significant datasets that will be used to enhance patient care, outcomes, and to further product innovations.
Details of the session: Polaroid Therapeutics & Avery Dennison Medical: How the power of partnership brings a novel approach to antimicrobial wound dressings.
SABIC advises the project was initiated together with the dialysis department at Jessa Hospital, one of the largest non-university medical cluster in the Limburg region of Flanders, Belgium.

By using this website you agree to accept Medical Device News Magazine Privacy Policy